Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
ESMO is sad to learn of the death of Professor Pierre Alberto, a wise and thoughtful oncologist whose clinical innovations and educational initiatives had a lasting impact.
Results from the studies with tucatinib, trastuzumab deruxtecan in patients with metastatic breast cancer
CXCR4 antagonist, BL-8040 modifies the tumour microenvironment
TMB is actively being studied as a predictive biomarker for identifying patients who might benefit from immunotherapy but the issue of variability between assays has been raised
Novel combination of sitravatinib and tislelizumab shows manageable safety and promising activity in phase Ib study
Results from analyses of safety, pharmacokinetics and immunogenecity in the CASPIAN trial
Results of the CheckMate 227 - part 2 final analysis
Two studies describe impact of the initiation of steroids early during the course of immune checkpoint inhibition on patient outcome
Nivolumab plus ipilimumab is effective regardless of PD-L1 expression levels in advanced NSCLC
Efficacy of pembrolizumab alone or combined with chemotherapy is solid regardless of KRAS mutations in non-squamous non-small cell lung cancer
The results from the ALCYONE study
Evidence for efficacy is based on the results from the IMpower130 study
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
